European cancer mortality predictions for the year 2022 with focus on ovarian cancer

Abstract

Background: Cancer mortality rates, though not absolute numbers of deaths, have been decreasing over the last three decades in Europe. Materials and methods: We estimated projections and the number of avoided deaths for total cancer mortality and 10 major cancer sites, between 1989 and 2022, for the European Union (EU), the UK, France, Germany, Italy, Poland and Spain using cancer death certification and population data since 1970 from the World Health Organization and Eurostat. Results: In the EU, we predict 1 269 200 cancer deaths in 2022; corresponding age-standardized rates (world) fall 6% to 126.9 deaths/100 000 in men and 4% to 80.2/100 000 women since 2017. Male lung cancer is expected to fall 10% reaching 30.9/100 000. The rise in female lung cancer mortality slowed (þ2% to 13.8/100 000). We estimated 369 000 (23%) avoided deaths in 2022 alone and a total of 5 394 000 (12%) deaths since the peak rate in 1988. Stomach, colorectal, breast and prostate cancers showed substantial declines, between 5% and 16% over the past 5 years. Pancreatic cancer remained stable in men (8.1/100 000) and rose 3% in women (5.9/100 000), becoming the third cause of cancer mortality in the EU (87 300 deaths), overtaking breast cancer (86 300 deaths). The fall in uterine cancers slowed down (À4%) to 4.7/100 000. Bladder cancer fell 9% in men, but was stable in women. Leukaemias fell more than 10%. Ovarian cancer mortality declined over the past decade in all considered countries. EU predicted rates were 4.3/100 000 (À13%) all ages, 1.2/100 000 (À26%) at 20-49, 15.3/100 000 (À11%) at 50-69 and 32.3/100 000 (À11%) at 70-79 years. Conclusions: We predicted additional declines in cancer mortality rates for 2022. The slowdown in female lung cancer mortality reflects some levelling of smoking in women. Favourable ovarian cancer trends are likely to continue and are largely attributable to the spreading oral contraceptive use and some impact of improved diagnosis and management.

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

“…Ovarian cancer is the leading cause of gynecologic cancer mortality in the US and the EU, despite the decrease of its mortality rate by 6.6% between 2017 and 2022, partly because of the use of oral contraceptives and the reduced use of hormone replacement therapy [ 1 ]. Its traditional median overall survival (OS) of around 50% at 5 years has been achieved with the forefront combination of debulking cytoreductive surgeries and platinum-based doublets, as well as chemotherapy rechallenge for subsequent relapses or progressions.…”

Primary Treatment Results in Patients with Ovarian, Fallopian or Peritoneal Cancer—Results of a Clinical Cancer Registry Database Analysis in Germany

“…All these questions should be considered carefully within the treatment and have significant influence on survival outcome measurements such as PFS and OS. The present analysis could demonstrate the high quality in standard of care of OC patients among the two federal states Berlin and Brandenburg regarding nationally and internationally published and well-established quality measurements [ 7 , 8 ]. There is also recent evidence that cancer mortality rates are decreasing ion Europe [ 8 ].…”

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer

“…It is estimated that about 19,880 2 of 19 will be diagnosed with ovarian cancer in the USA, according to the American cancer society [1]. Nevertheless, mortality is estimated to be reduced by 13% in the European Union in 2022 [2]. This reduction is believed to be due to the increased use of the oral contraceptive pill, the earlier diagnosis, and the advancements in the management of ovarian cancer.…”